OPEC+: Confusion Amidst Cuts

Expectations are set for a rise in oil prices in the upcoming year following voluntary output reductions by some members of OPEC+. If this happens, then gas prices will likely rise.

In a statement released on Thursday, the oil group stopped short of officially sanctioning production cuts. However, individual nations within the group have declared their own voluntary cutbacks, amounting to a total of 2.2 million barrels per day for the initial quarter of 2024.

Saudi Arabia, the leading member and a key player in OPEC, has decided to continue its voluntary cut of 1 million barrels per day, a policy that has been in effect since July through to the end of the first quarter of 2024.

Additionally, Russia announced its intention to reduce its supply by 300,000 barrels per day of crude oil and 200,000 barrels per day of petroleum products during this same timeframe.

The manner in which the production cuts were communicated contributed to confusion and skepticism among traders. Typically, OPEC+ would include all pertinent details in its press release regarding such announcements. However, this time around, on Thursday, the information was disseminated through separate statements from individual member states regarding their voluntary reductions.

The United Arab Emirates is reducing its oil production by 163,000 barrels per day (bpd), while Kuwait follows with a cut of 135,000 bpd. Kazakhstan is also making a significant reduction, slashing its output by 82,000 bpd. In a larger scale move, Iraq is decreasing its production by 223,000 bpd. Additionally, Algeria and Oman are contributing to the overall reduction, with Algeria cutting 51,000 bpd and Oman reducing by 42,000 bpd.

🎯 GRIT TAKE: The United States is on the verge of… upgrade to VIP to read the full GRIT take.

PFIZER: Weight Loss Drug Setback

On Friday, Pfizer announced its decision to discontinue the development of the twice-daily formulation of its experimental weight loss medication. This decision came after a mid-stage clinical trial showed that while obese patients lost weight using the drug, many experienced difficulties tolerating it.

The pharmaceutical company reported a high frequency of side effects in patients, predominantly of a mild gastrointestinal nature. Additionally, a considerable number of patients chose to discontinue the medication.

The recent findings regarding Pfizer's twice-daily weight loss medication represent a setback for the company's ambitions to secure a substantial portion of the rapidly expanding weight loss drug market. CEO Albert Bourla has previously estimated this market could expand to $90 billion, with Pfizer aiming for a $10 billion segment. The pharmaceutical giant is relying on a breakthrough in weight loss medication to compensate for the declining demand for its Covid-related products and to recover from a significant 40% decline in its share price this year.

However, investor confidence in Pfizer's prospects within the weight loss medication sector has been waning. This skepticism intensified after the company discontinued a different once-daily weight loss drug in June, opting instead to focus on danuglipron, which is perceived as a less promising option.

ROBINHOOD: CEO Holds Firm on Trading Controversy

Vlad Tenev, the CEO of Robinhood, maintains his belief that the payment for order flow (PFOF) model, a central component of the company's approach to routing orders to market-makers in the U.S., is not in jeopardy.

This perspective persists despite various influential consumer trading supporters and regulatory authorities advocating for a prohibition of the practice.

During a discussion with CNBC, Tenev upheld the PFOF method, characterizing it as a practice that is likely to endure. The PFOF model involves channeling trade orders to market-makers, such as Citadel Securities, in exchange for a share of the resulting profits.

The PFOF model is often seen as contentious due to the potential conflict of interest it poses between brokers and their clients.

Opponents of the practice argue that it motivates brokers to route orders to market makers who provide PFOF deals, potentially prioritizing these arrangements above their clients' interests.

Headlines You Need To Know: 🎙

• OpenAI tender offer is on track for January

• Tesla’s cheapest cyber truck will cost $60,990

• Oil’s wild ride is driven by bot traders

• Microsoft is happy being co-pilot on the OpenAI rocket ship

• Israel says Hamas violated terms of cease-fire

• Rate hikes are probably over

• Why it’s so hard to copy Charlie Munger’s secret sauce

• The big risk causing investors to shun China

Munger’s Tale of Strength Through Loss

Charlie Munger is widely recognized as a brilliant investor and the vice chairman of Berkshire Hathaway, where he has been Warren Buffett's right-hand man for decades. Munger's life, however, is a tapestry of profound triumphs and equally significant tragedies, painting a picture of resilience and intellectual growth.

Munger's journey into the world of business and investing had a tumultuous start. At the young age of 21, he faced a devastating setback, losing all his investments. This early failure, however, was not an endpoint but a foundation upon which Munger built his philosophy of thorough analysis and understanding of the intrinsic value of investments.

Tragedy struck again when Munger was 31. In an unforeseen and heart-wrenching turn of events, he lost his 9-year-old son, Teddy, to leukemia. This loss was not just emotional but also financial, as Munger had invested heavily in medical treatments for his son. The double blow of emotional and financial ruin could have deterred any individual, but Munger's resilience shone through.

Despite these adversities, Munger's career is marked by his remarkable comeback and success. His investment strategies and business acumen have been pivotal in the growth of Berkshire Hathaway. Munger is also known for his philanthropic efforts, wisdom in value investing, and his profound influence on global finance. His life story is a testament to overcoming personal and financial hardships through perseverance, intelligence, and an unwavering ethical compass.

Chart of the Day

📊 November 2023 was a historical month for the S&P. Will this strength continue and move into 2024?

The author, publisher or insiders of the publisher may currently have long or short positions in the securities of the companies mentioned herein, or may have such a position in the future (and therefore may profit from fluctuations in the trading price of the securities). To the extent such persons do have such positions, there is no guarantee that such persons will maintain such positions.